adriamycin - Robuta Search

https://www.mdpi.com/1422-0067/23/20/12691 Heparanase Increases Podocyte Survival and Autophagic Flux after Adriamycin-Induced Injury The kidney glomerular filtration barrier (GFB) is enriched with heparan sulfate (HS) proteoglycans, which contribute to its permselectivity. The... heparanase increases podocyte survival https://www.spandidos-publications.com/ol/10/4/2415 Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid... Oncology Letters is an international journal devoted to Experimental and Clinical Oncology. of the potentiation antitumor activity adriamycin https://www.spandidos-publications.com/10.3892/or.2014.3546/abstract Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p Oncology Reports is an international journal devoted to fundamental and applied research in Oncology. https://www.spandidos-publications.com/10.3892/mmr.2014.2734?text=fulltext Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of... Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery. quercetin enhances adriamycin cytotoxicity induction https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.659643/full Frontiers | Pilose Antler Peptide-3.2KD Ameliorates Adriamycin-Induced Myocardial Injury Through... Adriamycin (ADR)-based combination chemotherapy is the standard treatment for some patients with tumors in clinical, however, long-term application can cause... https://www.spandidos-publications.com/10.3892/or.18.2.353/abstract Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by... Oncology Reports is an international journal devoted to fundamental and applied research in Oncology. renal cell carcinoma https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1103013/full Frontiers | Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters... Background: Adriamycin-Cytoxan (AC) is a common chemotherapy treatment for breast cancer (BC) patients. Its electrolyte and hematological adverse effects hav... frontiers effects adriamycin cytoxan https://www.spandidos-publications.com/10.3892/mco.2014.272/abstract A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for... International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis. a retrospective combination therapy https://www.breastcancer.org/drugs/ACT-chemo AC-T Chemo Treatment: Adriamycin + Cytoxan + Taxol AC-T is a combination of three chemotherapy medicines that treat breast cancer. ac t chemo treatment adriamycin cytoxan https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-bortezomib-adriamycin-dexamethasone-as-first-treatment-for-myeloma-padimac A trial looking at bortezomib, adriamycin and dexamethasone as the first treatment for myeloma... This trial looked at a combination of bortezomib, adriamycin and dexamethasone (PAD) for myeloma.